Phaseline

Companies › Bio Meds Pharmaceutica Ltda

Bio Meds Pharmaceutica Ltda: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 4; Genitourinary; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Implantable gestrinone
Progestin (synthetic steroid hormone)
–Phase 4EndometriosisMar 2027
Oral Dienogest
Progestin (nortestosterone derivative)
–Phase 4EndometriosisMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06543550Implantable gestrinonePhase 4EndometriosisGenitourinaryMar 2027
NCT06543550Oral DienogestPhase 4EndometriosisGenitourinaryMar 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Vantive Health Fertility Center of Las Vegas Zydus Lifesciences Granata Bio Dimerix Bioscience

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.